Invitae Corporation Stock price

Equities

NVTA

US46185L1035

Biotechnology & Medical Research

Market Closed - Nyse 04:00:01 2023-12-05 pm EST Intraday chart for Invitae Corporation Pre-market 08:51:09 am
0.5862 USD -1.13% 0.59 +0.65%
Sales 2023 * 485M Sales 2024 * 524M Capitalization 168M
Net income 2023 * -1.43B Net income 2024 * -380M EV / Sales 2023 *
2,89x
Net Debt 2023 * 1.23B Net Debt 2024 * 1.08B EV / Sales 2024 *
2,38x
P/E ratio 2023 *
-0,11x
P/E ratio 2024 *
-0,45x
Employees 1,700
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.46%
More Fundamentals * Assessed data
Dynamic Chart
Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023 CI
Invitae Sells Certain Assets of YouScript Platform to Aranscia MT
Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer CI
Invitae Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Invitae Corporation, Q3 2023 Earnings Call, Nov 08, 2023 CI
Earnings Flash (NVTA) INVITAE CORPORATION Posts Q3 Revenue $121.2M, vs. Street Est of $121.1M MT
Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023 CI
Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing CI
Goldman Sachs Adjusts Price Target on Invitae to $0.50 From $1, Maintains Sell Rating MT
Invitae Names David Sholehvar Chief Operating Officer MT
Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023 CI
Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology CI
Invitae Receives US FDA Market Authorization for Common Hereditary Cancers Panel MT
FDA Gives Marketing Authorization to Invitae Test for Cancer Genes DJ
Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023 CI
More news
1 day-1.13%
1 week+14.92%
Current month+15.35%
1 month-7.67%
3 months-34.27%
6 months-44.70%
Current year-68.48%
More quotes
1 week
0.50
Extreme 0.5
0.64
1 month
0.36
Extreme 0.36
0.73
Current year
0.36
Extreme 0.36
2.94
1 year
0.36
Extreme 0.36
2.94
3 years
0.36
Extreme 0.36
61.59
5 years
0.36
Extreme 0.36
61.59
10 years
0.36
Extreme 0.36
61.59
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 2020
Founder 65 2010
Compliance Officer 52 2015
Members of the board TitleAgeSince
Director/Board Member 66 2015
Founder 65 2010
Director/Board Member 61 2010
More insiders
Date Price Change Volume
23-12-05 0.5862 -1.13% 5,686,040
23-12-04 0.5929 +2.54% 8,088,588
23-12-01 0.5782 +13.77% 7,309,324
23-11-30 0.5082 -1.78% 6,067,617
23-11-29 0.5174 +1.43% 6,485,546

Delayed Quote Nyse, December 05, 2023 at 04:00 pm EST

More quotes
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
0.5862USD
Average target price
1.31USD
Spread / Average Target
+123.47%
Consensus
  1. Stock
  2. Equities
  3. Stock Invitae Corporation - Nyse
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer